



European
Healthcare
Investor
Association

Delivering for Investors in Healthcare

September 2026



European
Healthcare
Investor
Association

At a Glance

Members and Partners

Membership Benefits

Membership Requirements

Appendix

AT A GLANCE

The European Healthcare Investor Association is the largest association of private capital providers investing in healthcare companies in Europe

Our aim is to provide networking and knowledge opportunities to our members, deliver sector focused market data and analysis, and promote a better understanding of investors' contribution to the healthcare economy

74

Members

€600bn+

AUM Source: Preqin

500+

Current healthcare portfolio
companies

SECTOR FOCUS

Healthcare Services

Healthcare

- Hospitals and Clinics
- Mental Health
- Dental
- Fertility
- Clinical Labs
- Diagnostics
- Staffing
- Primary Care
- Pharmacy
- Insurance
- Cosmetic & Aesthetics
- Consumer Healthcare
- Distribution
- Digital Health/Healthtech
- Funeral Services

Social Care & Education

Social Care

- Care Homes
- Homecare
- Complex Behavioural Care
- Supported Living
- Retirement Housing

Education

- Fostering
- SEN Schools
- Children's Residential Services
- Nurseries

Life Sciences & Pharma

Life Sciences

IVD

- Reagents
- Tools

Medtech

- Diagnostics
- Medical Devices and Implants
- Hospital Equipment
- Healthcare IT

Pharma

Manufacturing

- Generics
- Specialty Pharma
- OTC

Services

- CRO/CMO/CDMO
- Bioinformatics
- Medical Communications

Veterinary

- Veterinary Clinics

- Animal Health



European
Healthcare
Investor
Association

At A Glance

Members and Partners

Membership Benefits

Membership Requirements

Appendix



European
Healthcare
Investor
Association

INVESTOR MEMBERS

Funds range in size from €150m - €23bn with a focus on healthcare investing.

They include private equity, infrastructure and sovereign funds, foundations and family office investors



APPOSITE
CAPITAL LLP

astorg.

Bridgepoint

capiton

charterhouse



CVC

eci
building
successful
businesses

EURAZEO

Five Arrows



GBL

Gilde
HEALTHCARE

Gimv



H. I. G.
EUROPE

IK Partners



INVISION

JACOB
CAPITAL

KEENSIGHT
CAPITAL

LETTERONE
Health

Livingbridge

MTIP

NORDIC CAPITAL

Nordstjernen

novo
holdings



Riverside.

SUMMIT PARTNERS

Triton

Verlinvest

VITRUVIAN
PARTNERS

WATER STREET



European
Healthcare
Investor
Association

STRATEGIC PARTNERS & COLLABORATORS

We are supported by leading advisors in strategy consulting, law, real estate, investment banking, political & regulatory, insurance, executive recruitment and accounting.

Our partners are a key source of market insights for members and co-host many of our events.

Strategy Consulting



Investment Banking

J.P.Morgan

Legal



Regulatory Consulting



Executive Search



Accounting



Specialist Funding



Event Partner



Official Journal





European
Healthcare
Investor
Association

ASSOCIATE MEMBERS

We also work with other corporate entities that are neither Investor Members or Strategic Partners.

These include LPs and advisors who are not strategic partners.

Bevan Brittan 


law · tax · future


DC
advisory


eg technology


LATHAM & WATKINS^{LLP}

 Houlihan Lokey


Linklaters

 Rothschild & Co


PORTOLANO
CAVALLO


sermo



European
Healthcare
Investor
Association

At A Glance

Members and Partners

Membership Benefits

Membership Requirements

Appendix

SUMMARY OF MEMBER BENEFITS

Events & Networking

- Invitations to **exclusive dinners, breakfast seminars, networking drinks** including:
 - *Investors in Healthcare Gala Dinner in London (during Jefferies)*
 - *Autumn Networking Drinks in London*
 - *Women in Healthcare Investing networking events*
 - *Investors in Healthcare drinks in San Francisco (during JP Morgan)*
 - *Healthcare Investing in Germany Networking Dinner in Dusseldorf (during Medica)*
 - *European Healthcare & Life Sciences Investor Symposium in Frankfurt, Paris and London*
- Discounts to **industry events** including:
 - *Complimentary tickets* to Investors in Healthcare Private Capital Conference London (value £795 per ticket) * investor members only*
 - *Complimentary tickets* to Investors in Healthcare Real Assets Conference London (value £495 per ticket) * investor members only*
 - *Complimentary tickets* to McDermott's HPE Europe Conference London (value £795 per ticket) * investor members only*
 - *Discount to SuperReturn International (£1,200 per ticket)*
 - *Discount to SuperReturn Europe (£1,200 per ticket)*
 - *Discount to CPHI*
 - *Discount LSX World Congress London*
 - *Discount to Abu Dhabi Global Health Week*
- Opportunity to **partner** with EHIA on events with marketing support provided

Content & Community

- Access to exclusive Member-only Webinars and On-Demand content including:
 - *Healthcare Investing Insights with L.E.K. Consulting*
 - *Meet Your Members*
 - *Legal Insight with McDermott Will & Schulte*
- Monthly newsletter containing:
 - *Member-only content*
 - *Industry event calendar*
 - *Latest transactions, with advisors and valuations*
 - *Sector appointments*
- Complimentary Enterprise subscription to **Investors in Healthcare**, providing sector focussed news, data and analysis (value £1,495 p.a.)
- Industry engagement, sector news through web site, newsletters and LinkedIn: 20,000+ followers
- Promotion of your brand and investment activities to the EHIA community
- Membership includes access for an extensive number of team members per organisation (discretionary)
- Complimentary individual membership is also available to the CEOs of Investor members' portfolio companies

Value of membership benefits

£ Investors in Healthcare Gala Dinner £155	£ Discount to LSX Global Summit London £509
£ Complimentary tickets to MWE's HPE Europe Conference* £795	£ Discount to LSX Nordic Congress Copenhagen £240
£ Complimentary tickets to Investors in Healthcare Private Capital Conference London £795	£ Discount to LSX Investival Showcase London £425
£ Complimentary tickets to Investors in Healthcare Real Assets Conference London £495	£ Discount to CPHI £100
£ Discount to SuperReturn International £1,200	£ Complimentary subscription to Investors in Healthcare £295
£ Discount to SuperReturn Europe £1,200	£ Discounts are available to unlimited number of team members £

* Available to Investor members

Total value of benefits per person: £6,000+

COMMUNICATING WITH OUR MEMBERS

- Twice monthly newsletter
- Members-only content
- Industry events with members discounts
- Latest transactions, with advisors and valuations
- Sector appointments
- LinkedIn: 20,000+ followers
- Website



MEMBERS UPDATE

November 2025

NEW MEMBERS

We are delighted to welcome our most recent members




Investor Member Strategic Partner for Specialist Funding

Discover

FORTHCOMING EVENTS



Investors in Healthcare Gala Dinner

J.P.Morgan L&K London | 17 November 2025

McDermott Will & Schulte

London, 17 November: Scheduled to coincide with the first day of the Jefferies London Healthcare Conference, European Healthcare Investor Association is delighted to be hosting an exclusive gala dinner for healthcare investors and corporate CXOs. The event is generously supported by JP Morgan, McDermott Will & Schulte, L&K Consulting and Compass Carter Osborne.

Registration to this event is now closed as we have reached capacity. If you have accepted a place, we kindly request that you [advise us immediately](#) if you are no longer able to attend.



Investors in Healthcare Dinner

EBNER RSM DÜSSELDORF | 18th November 2025

Düsseldorf, 18 November: European Healthcare Investor Association in association with strategic partner RSM Ebner Stolz is delighted to host an exclusive invitation-only dinner for healthcare investors in



European Healthcare Investor Association (E.H.I.A.)

An association of investors, corporate leaders and advisors focussed on building successful healthcare businesses

Financial Services · London, England · 7K followers · 0-1 employees

Henry & 1 other connection work here

Message Following

Home About Posts Jobs People Insights



Investors in Healthcare

Convening knowledge and creating insights - the journal of the European Healthcare Investor Association

Business Intelligence Platforms · London · 12K followers · 2-10 employees

Frank & 1 other connection work here

Visit website Message Following

Home About Posts Jobs People Insights



News Roundup: November 2025

[Follow us on LinkedIn](#) [Listed on Google News](#)

The official journal of the European Healthcare Investor Association

Investors in Healthcare is a Google News listed digital resource delivering sector focussed news, data and analysis with an archive of 5,000+ articles.

Free access to all articles from the past month Access the full archive of 5,000+ articles & all data tables for £295

Register for free Subscribe

Complimentary subscription for EHIA Members

Contact [Sarah Ward](#) for a coupon code or to find out more about EHIA membership

INVESTORS IN HEALTHCARE REVIEW



A review of private capital healthcare investment in Europe

The third edition of this annual review includes content from EHIA Strategic Partners L&K Consulting, McDermott Will & Schulte, Marwood Group, Compass Carter Osborne, RSM and Howden Group, plus articles covering private versus public transactions, the case for global specialists in healthcare investing, and what healthcare assets are fundamental infrastructure.

View / Download

DEALS & NEWS





Complimentary
subscription

Healthcare
investing
focussed
news, data
and analysis

Listed on
Google News

5,000+ articles
searchable by
geography,
market and
subject


Data tables
covering M&A,
Equity and
Real Estate




The screenshot shows the homepage of the Investors in Healthcare website. The navigation bar includes links for News & Analysis, Markets, Geography, Rankings, and Resources. The main content area features several articles, including 'Technology: the backbone of healthcare's organic growth' by Nick Herbert, 'Finland: Jurriaan Dekkers appointed as CFO at Faron Pharmaceuticals' by Nick Herbert, and 'France: Charterhouse Capital Partners invests in Wibaux to accelerate international expansion plans'. There are also sections for Angelini and AXCEL.

Selected recent M&A deals

Date	Asset	Country	Est EV (\$m)	Article link	Buyer
12/09/2025	Zentiva	Czechia	4800	View article	GTCR
10/09/2025	DGr Pharma	Netherlands	N/D	View article	Keensight Capital
09/09/2025	Groupe Laboratoire Rivalis	France	N/D	View article	Archimed
08/09/2025	Luz Saúde	Portugal	1100	View article	Macquarie Asset Management, Maguarie European
08/09/2025	Alphal	Italy	N/D	View article	PAI Partners
04/09/2025	Atlantic Research Group (ARG)	UK	N/D	View article	Kester Capital
04/09/2025	A.foal retail & hospitality division	Belgium	N/D	View article	Abacus Medicine
02/09/2025	PK Benelux	Netherlands	N/D	View article	Avista Healthcare Partners
01/09/2025	STADA Arzneimittel	Germany	10000	View article	CapVest Partners
29/08/2025	Oudshoorn Chirurgische Techniek	Netherlands	N/D	View article	Asker Healthcare Group
28/08/2025	Novicare	Netherlands	N/D	View article	Gimv
27/08/2025	Centaur	Germany	770	View article	Unioninvest




The screenshot shows Google News search results for 'Equine Care Group GIMV'. The top result is from Investors in Healthcare, titled 'Belgium: Gimv joins forces with CNP to accelerate the global expansion of Equine Care Group', dated 6 days ago by Nick Herbert. Below it is a result from EU.COM titled 'Gimv backs Equine Care Group to accelerate global expansion', dated 5 days ago by Anjana Haines. Another result from EU.COM is titled 'Belgium: CNP to acquire E Group from Bencis', dated 21 Jul by Nick Herbert. A fourth result from EU.COM is titled 'Electra Partners rebrands', dated 5 days ago.



The screenshot shows the full article page on the Investors in Healthcare website. The article is titled 'Belgium: Gimv joins forces with CNP to accelerate the global expansion of Equine Care Group' by Nick Herbert, dated 27th November 2025. The article text states: 'European listed private equity investor Gimv is taking an indirect minority stake in Equine Care Group (ECG) from Belgian family-owned investor Compagnie Nationale à Portefeuille (CNP). ECG becomes one of Gimv's ten largest holdings. CNP will remain the firm's lead strategic partner. By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a shareholder group aiming to accelerate ECG's development into the world's leading one-stop partner for high-quality equine medicine. Xavier Le Clet, CEO, and David Caudron, CFO at CNP reckon that Gimv's healthcare expertise complements CNP's ambition and reinforces its shared mission to deliver world-class equine care and make this available all over the world.'

Strategic Partners benefit from complimentary banner advertising on Investors in Healthcare, a Google news listed site generating 170,000 annual visitors focused on healthcare and life science investing.



The screenshot shows the Investors in Healthcare website homepage. At the top is a dark blue navigation bar with the logo and links for News & Analysis, Markets, Geography, Rankings, Resources, and a shopping cart icon. Below the navigation bar is a large green banner for LEX with the text "Healthcare strategy. Investor impact." and the LEX logo. Underneath the banner is a "Most Popular" section with a grid of featured articles. The first article is "Singapore: UltraGreen.ai raises US\$400m from Singapore IPO" by Nick Herbert, dated 3rd December 2025, with a thumbnail image of surgeons in an operating room. Other articles in the grid include "UK: Pall Mall Medical acquires Birmingham hospital Kat & Co" (Clinical Labs), "Technology: the backbone of healthcare's organic growth" (Analysis), "France: Charterhouse Capital Partners invests in Wimback to accelerate international expansion plans" (Buy Out), and "Sweden: Anna Ryrberg joins Impilo as investment director" (Healthcare).



The screenshot shows the article page for "UK: Pall Mall Medical acquires Birmingham hospital Kat & Co" by Nick Herbert, dated 3rd December 2025. The article features a large photo of a man and a woman standing in front of a brick building. To the right of the article is a vertical advertisement for HODEN, titled "Global insurance and risk management specialists". Below the advertisement is another ad for "Unearthing rare talent to drive value creation" featuring a group of people.

Pall Mall Medical, a family-owned independent healthcare group and one of the UK's fastest-growing providers in the North-West, has acquired Kat & Co, a medical surgery and clinic in Birmingham led by consultant plastic surgeon [CC Kat](#).

The move marks a significant milestone in Pall Mall's expansion journey, strengthening its presence across the Midlands. As part of the acquisition, CC Kat will continue in her role as a practising surgeon within the business, ensuring continuity of care for patients.

This year Pall Mall celebrated its 15th anniversary, marking its growth from a single GP clinic to a healthcare provider with clinics in Manchester, Liverpool and Leeds, and a state-of-the-art private hospital in Newton-le-Willows. The business now employs more than 150 staff and delivers a wide range of services, from surgery and consultant-led appointments to advanced health screens, blood tests and diagnostic imaging including MRI, CT and X-ray.

Investors in Healthcare

A review of private capital healthcare investment in Europe

Delivering for investors in Healthcare

The largest association of private capital providers investing in healthcare companies in Europe

www.ehia.org

European
Healthcare
Investor
Association

Contact us
+44 (0)20 7737 0548
contact@ehia.org
www.ehia.org

Membership Enquiries
Sarah Ward Executive Director
sarah.ward@ehia.org

EHIA is a not-for-profit organisation

Registered in Scotland at the European
Healthcare Investor Association by
Carle Intelligence Ltd, The Kings Road,
115 Cowley Road, W1C 6JL
115 Cowley Road, W1C 6JL

© Carle Intelligence Ltd 2025

No responsibility can be taken by the
publisher or contributors for actions
taken as a result of information
provided in this publication. Readers
investing in part of this publication
may be represented in a personal
system, or transferred in any form of
any means, electronic, mechanical,
photocopying, recording, or otherwise
without either the prior written permission
of the publisher or a licence per-
mitting restricted copying issued by the
UK Copyright Licensing Agency
Ltd and in the USA by the Copyright
Clearance Center Inc.

Contents

Welcome	02
Member benefits	07
Investing in psychiatric therapies: market challenges and opportunities	09
Does the UK Life Science Sector need the US?	10
Private vs Public - still no clear winner	23
Life Sciences contracting: a transatlantic policy contrast	26
Healthcare investing is for global specialists	34
HPE Europe 2025: Key takeaways	36
Insuring a successful investment	42
McEuropa's Optegra exit highlights accelerating growth in European ophthalmology	47
What healthcare assets are fundamental infrastructure	50
Investors in Healthcare	54
AI, healthcare and private equity: Moving from pilots to value creation	56
Investor Members	62
Our Strategic Partners	63
In the Diary	65
Key Annual Events	65
Event Roundup	66
Working with Level 20	68
EHIA Conferences	69

Healthcare investing is for global specialists

Healthcare is complex with both risks and returns - knowledge and breadth are key

Authorised by Sarah Ward,
Executive Director of EHIA

Investors looking for outperformance when investing in private equity often look for single sector exposure - in fact nearly 20% of investors have this single sector exposure and it is a handful of sectors, namely energy, technology and healthcare.

While there have been private equity funds focused primarily or exclusively on healthcare in the US for many years, until recently that had not been the case in Europe. The US is a larger, deeper, more active market. So much so, that a not-for-profit trade association the HCPA (Healthcare Private Equity Association) was founded 20 years ago to support the healthcare private equity community in the US and Canada.

Of the Atlantic, driving this has been the focus on investment themes such as pharma services, HCT and medtech that are by their very nature global and where an understanding of and position in the US market is often critical for success.

Perhaps a more interesting development is that of funds focused exclusively on healthcare and Europe. Historically, a handful of generalist funds have had a very strong track record in European healthcare such as Bridgepoint, Cramer, BCP Partners, Blackstone, CVC, Hg Capital and S. Now there are a number of health-care-only funds in Europe, three with headquarters in London, one in France, and one in the Netherlands. The founders of these funds come with established track records in the industry, having held investment positions with firms such as ARCHIMED and GHD Capital and S. Now there are a number of health-care-only funds in Europe, three with headquarters in London, one in France, and one in the Netherlands. The founders of these funds come with established track records in the industry, having held investment positions with firms such as ARCHIMED and GHD Capital and S.

Knowledge in multiple markets can also be a competitive advantage - whilst the targeted fund managers such as Advent International, Apax, Bain, Blackstone, Hellman & Friedman and KKR have invested globally across healthcare and life sciences for some time, there are now larger European funds that are increasingly active in the US with fully staffed offices, with names such as Bridgepoint, BCP Partners, Cramer, CVC, EQT and Nordic Capital investing on both sides of the Atlantic.

Healthcare focused European funds

Fund Name	Investment Focus	Assets Under Management (AUM)	Key Partners
Imiplo	Healthcare	€1.5bn	Imiplo
Merieux	Healthcare	€1.5bn	Merieux
Lauxera	Healthcare	€1.5bn	Lauxera
Archimed	Healthcare	€1.5bn	Archimed
Goodgrower	Healthcare	€1.5bn	Goodgrower
Heathcare	Healthcare	€1.5bn	Heathcare
Apposite	Healthcare	€1.5bn	Apposite

Investment professionals and invest across healthcare services, information technology, pharmaceuticals and medical devices amongst others. Collectively, HCPA member firms have over \$4 trillion AUM and are invested in 1500+ healthcare businesses.

EHIA - the European landscape
The EHIA was founded just 4 years ago to support investors in Europe and there is a significant overlap between the two organisations - nearly 60% of HCPA member have an office in the UK, 20% of them have an office elsewhere in Europe, and 20% are also members of the EHIA. Existing members of both include Apax, Nordic and Novo Holdings. Novo is particularly interesting as a holding and investment company that is responsible for managing the assets and the value of the Novo Nordisk Foundation (currently 'Novo') is the world's largest philanthropic enterprise foundation focused on healthcare (more than twice the size of the Bill & Melinda Gates Foundation and the Wellcome Trust) and having started in Copenhagen, and now expanding in the US with offices and teams.

% of HCPA members with offices in UK and Europe (excl UK)

Year	% of HCPA members with offices in UK and Europe (excl UK)
2019	40%
2020	45%
2021	50%
2022	55%
2023	60%

HCPA member firms 2025

Firm Name	Assets Under Management (AUM)	Firm Name	Assets Under Management (AUM)
Apax Partners	€1.5bn	Imiplo	€1.5bn
Blackstone	€1.5bn	Merieux	€1.5bn
Bridgepoint	€1.5bn	Lauxera	€1.5bn
Cramer	€1.5bn	Archimed	€1.5bn
CVC	€1.5bn	Goodgrower	€1.5bn
EQT	€1.5bn	Heathcare	€1.5bn
Hellman & Friedman	€1.5bn	Apposite	€1.5bn
KKR	€1.5bn		
Novo Holdings	€1.5bn		
Novo Nordisk Foundation	€1.5bn		
Novo Nordisk	€1.5bn		
Novo Nordisk Foundation	€1.5bn		
Novo Nordisk	€1.5bn		
Novo Nordisk Foundation	€1.5bn		
Novo Nordisk	€1.5bn		
Novo Nordisk Foundation	€1.5bn		
Novo Nordisk			

PRIVATE CAPITAL REVIEW

Our Strategic Partners are invited to contribute an editorial article to the annual Private Capital Review, and a complimentary full-page advert.



INVESTORS IN HEALTHCARE

“Digital tools can extend therapy reach, support patients between sessions, and standardize aspects of treatment that currently vary widely.”

Finally, continued research into treatment mechanisms will be vital. One of the most important outstanding questions is whether the methods are therapeutic in their own right or whether their primary value lies in catalyzing therapeutic change.

Early data sets, such as Compas Partners’ 2-million-chart study, suggest a dose-dependent pharmacological effect. If future evidence confirms this, it could allow therapies to be administered under supervision by healthcare professionals or even licensed psychotherapists, reducing workload and increasing accessibility.

It would also align more closely with existing regulatory models, in which approval is based on efficacy and safety of drugs rather than psychotherapies.

Conclusion

The emergence of psychodiagnostics is an unfolding commercial reality that could reshape mental health treatment in the coming decade. Late-stage clinical trials are already delivering promising results, and while hurdles remain, the path to commercialization is becoming clearer.

For investors, the sector offers exposure to a high-growth market with the potential to reshape the way the infrastructure that has blighted whether these treatments can be delivered at scale. ■

HOW U.S.K. CAN HELP

As mental health awareness and regulatory oversight rise in the healthcare system, we help organizations address a range of key issues, creating value for top provider clients and their shareholders. We leverage our deep experience with their commercial and growth strategy, supporting them in general sector and in particular, to drive the approach. We help organizations commercialize a better solution, rather than just a better idea, and we help them create greater shareholder returns.

We find out what you need for a candid discussion, share contact information, invite further.

results on promising questions remain about how these therapies will perform in routine practice and how they will be supported by regulatory, medical systems and payers.


Emerging solutions

Despite these hurdles, there are clear paths forward. Some can be represented as areas of opportunity and others as constraints. Improving existing standards, ensuring high quality, and making sure that resources available, payers, accelerate guideline development and help integrate psychotherapy, enabled therapy into psychiatric practice.

Digital approaches are another area of promise. Clinical tools can extend the impact, match patient patterns between sessions, and standardize aspects of treatment that currently vary widely. They may also serve in diagnostics, improving the ease of prescription.

Digital therapies are one of the behavioral health conditions.

While models of care also merit consideration, while doing so, others must be taken into account, including preparatory and integration support that be delivered in group settings, especially reducing therapy demand in parallel. Examples of therapy could be delivered in less specialized and well trained staff, a strategy known as task shifting, which has proven effective in other areas of global health. This approach may be particularly relevant in low- and middle-income countries, where specialized resources are scarce.



LEK

**Strategy That Powers
Healthcare and Investment**

From market access and digital health to M&A and value creation, our global team **empowers organisations** to thrive in an era of rapid change

Healthcare Services | MedTech | Life Sciences

lek.com

Life Sciences Contracting;

A Transatlantic Policy Contrast

26

A laboratory setting with a pipette dispensing liquid into test tubes. The background is a soft-focus image of several glass test tubes and a pipette tip, suggesting a scientific or healthcare environment. The lighting is cool and blue-toned.

J.P.Morgan

Global **strength**.
World-class **expertise**.
Commitment you can count on.

J.P. Morgan is proud to sponsor
the European Healthcare
Investor Association.

© 2025 JPMorgan Chase & Co. All rights reserved.

[illegible][illegible]

INVESTING IN HEALTHCARE

AI, healthcare and private equity:

Moving from pilots to value creation

IDEAL INC.

For private equity houses, AI is not only redefining the ways teams analyze investments, manage portfolios and create value. It has also become an important factor in whether to invest in a company or not. In the UK's healthcare sector, AI holds the potential for improving patient outcomes and improving operational efficiency. To generate superior returns, private equity (PE) houses need to understand the six strategies of potential investments as well as how the technology can be used as a value creation tool across their portfolios.

A powerful transformation tool because its capabilities can be scaled in a wide variety of ways. And, unlike any other technology, you're betting on it to overcome repetitive tasks, improve time to market and drive decision-making. The only way can be improved to meet individual and team needs. Add in its capacity for learning, adaptation and personalization and it's clear how this technology is going to be a winning strategy in the years ahead.

But the reality of AI implementation has proven more complicated. Across the European healthcare sector, the picture is patchy: some companies have tried to make it work, while other organizations have never even got started. And across the public and private sectors, there are some good

use cases with clear benefits emerging – but these are yet to be fully scaled. Despite all the noise and hype, a 2018 survey found that 71% of all healthcare professionals reported never using AI at work.

So, what's gone wrong? The answer lies in how AI is implemented across the healthcare space. It's not enough to just increase its implementation across the healthcare space. The world could be lost only factor private equity, but faster value creation for its investors. The solution will be to use AI to create value across the healthcare space and to create value across the healthcare space.

The focus now shifts from technical feasibility to commercial viability. The central question for investors is no longer can these technologies work, but how do they work? And how do they create value? The answer lies in the value creation model, margins and value creation.

34

INVESTING IN HEALTHCARE

INVESTING IN HEALTHCARE

INVESTING IN HEALTHCARE

Insuring a successful investment

Howard Binstock, CMO

Investing in a healthcare or life sciences business can present its own unique challenges—not least getting sufficient asset and insurance in place. As every investment banker, crafting a policy that is tailored to each particular target company is critical when ensuring every asset and eventually its owners. However, there are certain elements that, first place, can protect a company against future challenges.

Working with the regulator

For those firms with an healthcare or life sciences business, it is a high brick that the company must clear before it can get on with its business and, if necessary, an insurance policy will be central to it. In fact, for many companies across the authorities to ensure they are aware and understand, rather than a challenging regulatory minefield. However, there are a number of things that companies can do to ensure they are working with the regulator and avoiding any problems in the future. Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Dealing with reputational risk

The risk of reputational damage is a significant one for any company, particularly in the healthcare and life sciences sectors. It can be particularly damaging if it is linked to a product or service that is critical to the company's success. Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

“Many private equity firms have the aim of growing a business in order to maximize their returns.”

be associated with a reputational damage to an essential aspect to consider when carrying out due diligence on these types of companies.

Ensuring insurance does not block growth. Many private equity firms have the aim of growing a business in order to maximize their returns. However, it is important to ensure that the insurance policy does not block growth. Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Sub-contractors

It is also important to ensure there is adequate insurance to cover any sub-contractors, such as doctors, consultants and life scientists. Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

Insurance across jurisdictions

It is important to ensure there is adequate insurance to cover any sub-contractors, such as doctors, consultants and life scientists. Companies should ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them. They should also ensure they are aware of the relevant regulatory requirements and ensure they are compliant with them.

42

43

LIVE EVENTS & WEBINARS

Invitations to healthcare breakfasts & dinners, report launches and networking drinks receptions


Complimentary tickets to Private Capital Conference and Real Assets Conference

Investing in Healthcare Insights with L.E.K. Consulting

“Meet your Member” webinars with portfolio company CEO presentations and Q&A including with the lead investor from the fund

In the Diary: calendar of third-party healthcare events

Discounts on partnered events globally including SuperReturn, HPE Europe, CPHI



INVESTORS IN HEALTHCARE CONFERENCES

Complimentary tickets for investor members tour annual Private Capital Conference (June) and Real Assets Conference (February)




RESOURCE & MEMBER HUBS

The latest research, reports and sector guides from our Strategic Partners

Sector focused market data and analysis

On Demand webinars

Curis: Proprietary portfolio & deal database



Resource Hub

Browse Resources

REPORTS AND GUIDES

FREE TO VIEW WEBINARS

PODCAST

OFFICIAL JOURNAL

Members Only

ON DEMAND WEBINARS

TRADE ASSOCIATIONS



Members Hub

EXCLUSIVE CONTENT

MEET YOUR MEMBERS

STRATEGIC PARTNER CONTENT

- Apax Partners and Rodenstock Group
- Eurazeo and Dorc
- McDermott Will & Emery
- ***REGULATORY ALERT*** - New EU filing from October for MSA deals

Reports and Guides

The Compass 2025: Healthcare Insights for Europe
Vikas Yadav | October 27, 2025
Marwood Group

Is Generative AI Worth the Hype in Healthcare?
GenAI is reshaping healthcare through smarter tools and improved efficiency, though integration and regulation still pose challenges.
LEK Consulting

The Next Decade of Health: Inside the NHS 10-Year Plan
Adam Nightingale, Ruby Kleyer, and Dr. Vikas Yadav | July 30, 2025
Marwood Group

Meet your Members

Apax Partners and Rodenstock Group
9am, Thursday 24th February

Exclusive access to our new CEO/Sponsor webinar series - listen to the story behind the investment of a current portfolio company of an association member, followed by Q&A.

Watch on YouTube

DOWNLOAD SLIDES



curis

HOME INVESTOR ASSET SEARCH SARAH WARD

The definitive database of healthcare private equity

Quick Search

433 INVESTORS

1780 FUNDS

2573 ASSETS

4931 PEOPLE

2390 ADVISORS

Novo Holdings
Private Equity Firm
Tuborg Havnevej 19, Hellerup, 2900, Denmark
Skip to: Funds Assets Contacts

Overview

Established	
Secondary Offices	San Francisco CA US; Singapore Singapore; London UK
Investment Geographies	
Sectors	Life Sciences & Pharma
SubSectors	Life Sciences

Contact Information

Telephone	Info@novoholdings.dk
Email	+45 3527 6500
Website	https://novoholdings.dk/

Assets

Asset	Hold Period
Oxeno - 15 Years 8 Months	
Xelixa Pharmaceuticals - 12 Years 7 Months	
Sonion - 11 Years 4 Months	
Enxide - 8 Years 10 Months	
ConvaTec Group plc - 8 Years 8 Months	



European
Healthcare
Investor
Association

At A Glance

Members and Partners

Membership Benefits

Membership Requirements

Appendix

Member type	Requirements	Price per annum
1. Investor Member	Investment funds active in healthcare comprising private equity, infrastructure, sovereign funds, foundations, real estate investors and family offices that meet the following criteria: • More than €200m AUM • Two or more current or former healthcare portfolio companies or assets • Two or more nominated healthcare-focused investment professionals	£3,995
2. Associate Member	There are two tiers of Associate Membership available. One is for Corporate entities within the healthcare sector; the other is for Advisors active in the healthcare sector that are not Strategic Partners.	Corporate: £4,250 Advisory: £4,950
3. Strategic Partner	Advisors active in the healthcare sector who support the Association with content and events.	£6,500
4. Individual Member	Individual membership is specifically reserved for current or former CEOs, Chairs, or Non-Executive Directors of portfolio companies of investors who satisfy the membership criteria (see above). This is designed to facilitate interactions between investors and leading executives within the sector. Applicants must hold or have held a C-suite position in a portfolio company of an investor who meets our membership criteria. It is not a requirement for the investor to be a member of EHIA, although they may be.	£575



European
Healthcare
Investor
Association

At A Glance

Members and Partners

Membership Benefits

Membership Requirements

Appendix

KEY PEOPLE



Alan McKay
Chairman

Alan is an Executive Partner and co-founder of GH0 Capital and has been a private equity investor for 30 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. Alan has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He was Chair of the BVCA for 2016 – 2017 and has chaired its Responsible Investment Advisory Board. Global Healthcare Opportunities, or GH0 Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. The firm was built from a shared experience and long-standing history of creating and backing businesses, accelerating growth, delivering value and championing success in the sector through prior roles with healthcare industry leader Quintiles, 3i Group, J.P. Morgan and TPG.



Henry Elphick
Deputy Chair

Henry is Chair of Mansfield Advisors LLP, a leading strategy consultancy specialising in health and care provision, life sciences, and medtech focussing on commercial due diligence and corporate strategy projects with broad clinical, consulting, and international experience. He is also a Senior Consultant to the global financial services group Macquarie, Non-Executive Chairman of Compass Holding Group, and Deputy Chair of the European Healthcare Investor Association. Previously, Henry was CEO of LaingBuisson for 5 years and had a 20-year career advising healthcare companies as an investment banker with Jefferies, UBS and Rothschild having qualified as a solicitor with Linklaters. He is also a trustee of the charity Turn2Us, an advisor to the International Longevity Centre think tank and formerly the Chairman for eight years of care home provider Elizabeth Finn Homes. He has an MA in Law from the University of Oxford.



Sarah Ward
Executive Director

Sarah leads the strategic direction and day-to-day operational management of EHIA, working in close collaboration with members and partners to deliver on the organisation's mission - enhancing networking, advancing digital innovation, and developing new data tools to support private equity investment in healthcare. In recognition of her impact, Sarah was honoured with inclusion on the 'Women in Trade Associations 2025 Power List' in March 2025. She also oversees the strategic vision of Investors in Healthcare, the official journal of EHIA. Sarah is regularly invited to serve as a judge for the PPA Awards, which celebrate excellence across the independent publishing sector. Previously, Sarah held the role of Commercial Director at LaingBuisson, bringing extensive expertise in business development, marketing strategy, digital platform innovation, data-driven tools, and event leadership.

OUR GOVERNANCE

EHIA is a not-for-profit organisation answerable to its members in the annual general meeting. Our members are investors, current and former board members and corporate leaders of portfolio companies and advisors to the healthcare private equity community.

Articles of Association

[VIEW](#)

Certificate of incorporation

[VIEW](#)



European
Healthcare
Investor
Association

CONTACT US



EHIA
11-13 Cavendish Square
London
W1G 0AN
United Kingdom

+44 (0)20 7173 0548

contact@ehia.org

[Website](#)

[LinkedIn](#)